XML 27 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Sep. 30, 2023
Current assets:    
Cash, cash equivalents and restricted cash $ 127,704 $ 110,891
Available-for-sale securities, at fair value 395,410 292,735
Prepaid expenses 11,022 8,813
Other current assets 7,514 7,082
Total current assets 541,650 419,521
Property, plant and equipment, net 359,252 290,262
Intangible assets, net 9,412 10,262
Right-of-use assets 44,626 45,297
Other assets 210 210
Total Assets 955,150 765,552
Current liabilities:    
Accounts payable 8,521 35,866
Accrued expenses 37,055 39,763
Accrued payroll and benefits 13,741 17,963
Lease liabilities 5,285 10,563
Deferred revenue 0 866
Other liabilities 573 435
Total current liabilities 65,175 105,456
Long-term liabilities:    
Lease liabilities, net of current portion 113,632 104,608
Liability related to the sale of future royalties 280,938 268,326
Total long-term liabilities 394,570 372,934
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders’ equity:    
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 124,133 and 107,312 shares 217 200
Additional paid-in capital 1,768,866 1,300,395
Accumulated other comprehensive loss (1,095) (3,222)
Accumulated deficit (1,284,194) (1,026,030)
Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity 483,794 271,343
Noncontrolling interest 11,611 15,819
Total noncontrolling interest and stockholders’ equity 495,405 287,162
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity $ 955,150 $ 765,552